ERBB2 and neoplasm: In contrast, the highly immunogenic CT26-HER2 tumor was recognized by the immune system and appeared to actively fight for its survival by adopting several strategies (CTLA-4, LAG3, PD1, and Tregs) that reverse the activity of the antitumor immune effectors.